Interleukin 8 promoter polymorphism predicts the initial response to bevacizumab treatment for exudative age-related macular degeneration

Retina

Volumn 33, Issue 9, 2013, Pages 1815-1827

  Hautamäki, Asta ^a   Kivioja, Jarno ^b   Vavuli, Satu ^c,d   Kakko, Sakari ^d   Savolainen, Eeva Riitta ^e   Savolainen, Markku J ^d   Liinamaa, M Johanna ^c,d   Seitsonen, Sanna ^a   Onkamo, Päivi ^b   Järvelä, Irma ^b   Immonen, Ilkka ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c Institute of Clinical Medicine   (Finland)

^d UNIVERSITY OF OULU   (Finland)

^e OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

bevacizumab; exudative AMD; interleukin 8; optical coherence tomography; pharmacogenetics; single nucleotide polymorphism; treatment response

Indexed keywords

BEVACIZUMAB; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; DNA; ERYTHROPOIETIN; INTERLEUKIN 8; VASCULOTROPIN;

ADULT; AGED; ALLELE; ARTICLE; EXUDATIVE MACULAR DEGENERATION; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MEDICAL RECORD; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; TREATMENT RESPONSE; VISUAL ACUITY;

EID: 84885022545     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e318285cf92     Document Type: Article

References (59)

1. The CATT Research Group. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
2. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-583.
3. Lalwani G, Rosenfeld P, Fung A, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol 2009;148:43-58.e1.
4. Devaraj S, Kumaresan PR, Jialal I. Effect of C-reactive protein on chemokine expression in human aortic endothelial cells. J Mol Cell Cardiol 2004;36:405-410. (Pubitemid 38316945)
5. Wang Y, Bian ZM, Yu WZ, et al. Induction of interleukin-8 gene expression and protein secretion by C-reactive protein in ARPE-19 cells. Exp Eye Res 2010;91:135-142.
6. DeForge LE, Preston AM, Takeuchi E, et al. Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem 1993;268:25568-25576. (Pubitemid 23358166)
7. Stentz FB, Kitabchi AE. Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidation. Biochem Biophys Res Commun 2006;346: 721-726.
8. Strieter RM, Kunkel SL, Showell HJ, et al. Endothelial cell gene expression of a neutrophil chemotactic factor by TNFalpha, LPS, and IL-1 beta. Science 1989;243:1467-1469. (Pubitemid 19087129)
9. Higgins GT, Wang JH, Dockery P, et al. Induction of angiogenic cytokine expression in cultured RPE by ingestion of oxidized photoreceptor outer segments. Invest Ophthalmol Vis Sci 2003;44:1775-1782. (Pubitemid 36378609)
10. Kurji KH, Cui JZ, Lin T, et al. Microarray analysis identifies changes in inflammatory gene expression in response to amyloidbeta stimulation of cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 2010;51:1151-1163.
11. Abdel-Malak NA, Srikant CB, Kristof AS, et al. Angiopoietin-1 promotes endothelial cell proliferation and migration through AP-1-dependent autocrine production of interleukin-8. Blood 2008;111:4145-4154.
12. Mizukami Y, Jo WS, Duerr EM, et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005;11:992-997. (Pubitemid 41294446)
13. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem 2009;284:6038-6042.
14. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000;55:1023-1027.
15. Taguchi A, Ohmiya N, Shirai K, et al. Interleukin-8 promoter polymorphism increases the risk of atrophic gastritis and gastric cancer in Japan. Cancer Epidemiol Biomarkers Prev 2005; 14:2487-2493. (Pubitemid 41752706)
16. Ohyauchi M, Imatani A, Yonechi M, et al. The polymorphism interleukin 8-251 A/T influences the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population. Gut 2005;54:330-335. (Pubitemid 40299086)
17. Hildebrand F, Stuhrmann M, van Griensven M, et al. Association of IL-8-251A/T polymorphism with incidence of acute respiratory distress syndrome (ARDS) and IL-8 synthesis after multiple trauma. Cytokine 2007;37:192-199. (Pubitemid 46880388)
18. Wang Z, Shao J, Zhou Q, et al. The-251A.T polymorphism of interleukin-8 is associated with longer mechanical ventilation and hospital staying after coronary surgery. Cytokine 2010;50:268-272.
19. Schultheis AM, Lurje G, Rhodes KE, et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14: 7554-7563.
20. Goverdhan SV, Ennis S, Hannan SR, et al. Interleukin-8 promoter polymorphism-251A/T is a risk factor for age-related macular degeneration. Br J Ophthalmol 2008;92:537-540. (Pubitemid 351497986)
21. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114:2168-2173. (Pubitemid 350181136)
22. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89:e344-e349.
23. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93:610-613.
24. Teper SJ, Nowinska A, Pilat J, et al. Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration. Mol Vis 2010;16:2598-2604.
25. Kloeckener-Gruissem B, Barthelmes D, Labs S, et al. Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4694-4702.
26. McKibbin M, Ali M, Bansal S, et al. CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. Br J Ophthalmol 2012;96:208-212.
27. Immonen I, Seitsonen S, Tommila P, et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 2010;117:103-108.
28. Tong Z, Yang Z, Patel S, et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc Natl Acad Sci USA 2008;105:6998-7003. (Pubitemid 351754519)
29. Abhary S, Burdon KP, Casson RJ, et al. Association between erythropoietin gene polymorphisms and diabetic retinopathy. Arch Ophthalmol 2010;128:102-106.
30. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment-TAP and VIP report no. Arch Ophthalmol 2003; 121:1253-1268.
31. Seitsonen SP, Onkamo P, Peng G, et al. Multifactor effects and evidence of potential interaction between complement factor H Y402H and LOC387715 A69S in age-related macular degeneration. PLoS One 2008;3:e3833.
32. Ma W, Kantarjian H, Zhang K, et al. Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome. BMC Med Genet 2010;11:163.
33. Ito H, Matsuo K, Hamajima N, et al. Significant association of interleukin 8-251T/A polymorphism with smoking behavior in a Japanese population. J Hum Genet 2005;50:567-573. (Pubitemid 41666976)
34. Belperio JA, Keane MP, Arenberg DA, et al. CXC chemokines in angiogenesis. J Leukoc Biol 2000;68:1-8.
35. Li A, Dubey S, Varney ML, et al. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170: 3369-3376. (Pubitemid 36302216)
36. Petreaca ML, Yao M, Liu Y, et al. Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability. Mol Biol Cell 2007;18:5014-5023. (Pubitemid 350246701)
37. Talavera D, Castillo AM, Dominguez MC, et al. IL8 release, tight junction and cytoskeleton dynamic reorganization condu-cive to permeability increase are induced by dengue virus infection of microvascular endothelial monolayers. J Gen Virol 2004;85:1801-1813. (Pubitemid 39023258)
38. Roh MI, Kim HS, Song JH, et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 2009; 116:80-86.
39. Funk M, Schmidinger G, Maar N, et al. Angiogenic and inflammatory markers in the intraocular fluid of eyes with diabetic macular edema and influence of therapy with bevacizumab. Retina 2010;30:1412-1419.
40. Sohn HJ, Han DH, Kim IT, et al. Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema. Am J Ophthalmol 2011;152:686-694.
41. Kramer M, Goldenberg-Cohen N, Axer-Siegel R, et al. Inflammatory reaction in acute retinal artery occlusion: cytokine levels in aqueous humor and serum. Ocul Immunol Inflamm 2005;13:305-310. (Pubitemid 41702774)
42. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-1032.
43. Fonollosa A, Garcia-Arumi J, Santos E, et al. Vitreous levels of interleukine-8 and monocyte chemoattractant protein-1 in macular oedema with branch retinal vein occlusion. Eye 2010;24:1284-1290.
44. Zhu D, Deng X, Xu J, Hinton DR. What determines the switch between atrophic and neovascular forms of age related macular degeneration? The role of BMP4 induced senescence. Aging 2009;1:740-745.
45. Roh MI, Kim HS, Song JH, et al. Concentration of cytokines in the aqueous humor of patients with naive, recurrent and regressed CNV associated with AMD after bevacizumab treatment. Retina 2009;29:523-529.
46. Forooghian F, Kertes PJ, Eng KT, et al. Alterations in the intraocular cytokine milieu after intravitreal bevacizumab. Invest Ophthalmol Vis Sci 2010;51:2388-2392.
47. Steinbrugger I, Haas A, Maier R, et al. Analysis of inflammationand atherosclerosis-related gene polymorphisms in branch retinal vein occlusion. Mol Vis 2009;15:609-618.
48. Maier R, Steinbrugger I, Haas A, et al. Role of inflammationrelated gene polymorphisms in patients with central retinal vein occlusion. Ophthalmology 2011;118:1125-1129.
49. Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet 2001;69:413-419. (Pubitemid 32695212)
50. LeeWP, Tai DI, Lan KH, et al. The-251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res 2005;11:6431-6441.
51. Tsai YY, Lin JM, Wan L, et al. Interleukin gene polymorphisms in age-related macular degeneration. Invest Ophthalmol Vis Sci 2008;49:693-698.
52. Nakata I, Yamashiro K, Nakanishi H, et al. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 2011;55:435-443.
53. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-252. (Pubitemid 46172497)
54. Kaiser P, Brown D, Zhang K, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007;144:850-857.e4.
55. Sadda SR, Liakopoulos S, Keane PA, et al. Relationship between angiographic and optical coherence tomographic (OCT) parameters for quantifying choroidal neovascular lesions. Graefes Arch Clin Exp Ophthalmol 2010;248:175-184.
56. Ting TD, Oh M, Cox TA, et al. Decreased visual acuity associated with cystoid macular edema in neovascular age-related macular degeneration. Arch Ophthalmol 2002;120:731-737. (Pubitemid 34620351)
57. Cao R, Jensen LD, Soll I, et al. Hypoxia-induced retinal angiogenesis in zebrafish as a model to study retinopathy. PLoS One 2008;3:e2748.
58. Perez-Santonja JJ, Campos-Mollo E, Lledo-Riquelme M, et al. Inhibition of corneal neovascularization by topical bevacizumab (anti-VEGF) and sunitinib (anti-VEGF and anti-PDGF) in an animal model. Am J Ophthalmol 2010;150:519-528.e1.
59. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-1071.